Stocklytics Platform
Asset logo for symbol PRME
Prime Medicine
High Growth
Asset logo for symbol PRME


Key Stats
Prev. Close$6.29
Next Earnings Date-
Dividend Yield %-
PE Ratio-
Day Range5.42
52 Week Range4.11
EBITDA Margin %-
Gross Profit-
Payout Ratio-
Industry average yield2.86%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_down0.15%
US Marketarrow_drop_up0.90%
PRME / Market
PRME lose to the US Market which returned 0.90% over the last twenty four hours.
PRME / Healthcare Sector
PRME lose to the US Healthcare sector which returned -0.15% over the last twenty four hours.

Prime Medicine (PRME) Statistics

Prime Medicine, Inc. (PRME) is a leading biotechnology company that specializes in the development of innovative therapies and treatments. With a focus on prime editing, the cutting-edge gene editing technology, PRME is at the forefront of medical advancements. The company's mission is to harness the power of prime editing to revolutionize the field of medicine and provide patients with life-changing treatments. PRME's commitment to scientific excellence is reflected in its strong valuation metrics. The company's stock has been performing exceptionally well, outperforming the sector consistently. PRME's revenue per share has also shown impressive growth, indicating the company's ability to generate substantial revenue from its products and services.

One important metric that investors consider when evaluating a company's financial health is the enterprise to EBITDA ratio. This ratio helps determine the company's ability to generate cash flow from its operations. PRME has demonstrated a favorable enterprise to EBITDA ratio, indicating its efficiency in utilizing its assets to generate profits. Furthermore, PRME's profit margin is another notable metric, reflecting the company's ability to control costs and generate a healthy return on its investments. With a strong profit margin, PRME is well-positioned for future growth and profitability. In terms of financial stability, PRME has maintained a low level of total debt, indicating a conservative approach to financing and a solid balance sheet. This provides investors with confidence in the company's ability to weather economic challenges and sustain its growth. Additionally, PRME's gross profit has shown consistent growth over the years, illustrating the company's ability to generate profits after accounting for the cost of goods sold.

add Prime Medicine to watchlist

Keep an eye on Prime Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

What is the EPS of Prime Medicine (PRME) stock?

The Earnings Per Share (EPS) for Prime Medicine (PRME), calculated on a diluted basis, is -$2.18. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

How much debt does Prime Medicine (PRME) have?

Prime Medicine (PRME) has a total debt of $43.79M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$50.37M.

What is the PE ratio of Prime Medicine (PRME) stock?

The PE ratio for Prime Medicine (PRME) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the operating margin of Prime Medicine (PRME) stock?

The operating margin for Prime Medicine (PRME) is -8.18K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Prime Medicine (PRME) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Prime Medicine (PRME) is -$194.68M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How has Prime Medicine (PRME) stock's performance compared to its sector and the market over the past year?

Over the past year, Prime Medicine (PRME) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.13%, Prime Medicine has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 50.53%, it has fallen short of the market average. This comparison highlights Prime Medicine's performance relative to both its sector and the overall market over the last year.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level